Last reviewed · How we verify
Fexofenadine HCl New Formulation Tablet — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Fexofenadine HCl New Formulation Tablet (Fexofenadine HCl New Formulation Tablet) — Opella Healthcare Group SAS, a Sanofi Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fexofenadine HCl New Formulation Tablet TARGET | Fexofenadine HCl New Formulation Tablet | Opella Healthcare Group SAS, a Sanofi Company | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fexofenadine HCl New Formulation Tablet CI watch — RSS
- Fexofenadine HCl New Formulation Tablet CI watch — Atom
- Fexofenadine HCl New Formulation Tablet CI watch — JSON
- Fexofenadine HCl New Formulation Tablet alone — RSS
Cite this brief
Drug Landscape (2026). Fexofenadine HCl New Formulation Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/fexofenadine-hcl-new-formulation-tablet. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab